Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Takeda Files Selective Intregrin Antagonist Vedolizumab For IBD

This article was originally published in The Pink Sheet Daily

Executive Summary

Takeda’s drug is in the same family as Biogen Idec’s Tysabri, but is more selective and theoretically safer; no PML cases have been reported for vedolizumab in trials to date. Roche and Pfizer also have different kinds of selective integrin antagonists in development for IBD.

Advertisement

Related Content

Takeda’s Vedolizumab Better At Inducing Response In Ulcerative Colitis Than Crohn’s Disease
Takeda’s Vedolizumab Better At Inducing Response In Ulcerative Colitis Than Crohn’s Disease
Takeda’s Vedolizumab Better At Inducing Response In Ulcerative Colitis Than Crohn’s Disease
Gastroenterology Endpoints For IBD Drugs Once Again In FDA Spotlight
Millennium/Takeda’s Phase III IBD Drug Promises Improved Safety

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS075868

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel